Content
August 2017, Volume 35, Issue 8
- 817-830 A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models
by Chase Hollman & Mike Paulden & Petros Pechlivanoglou & Christopher McCabe - 831-844 Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
by Min Huang & Yanyan Lou & James Pellissier & Thomas Burke & Frank Xiaoqing Liu & Ruifeng Xu & Vamsidhar Velcheti - 845-858 Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis
by James Buchanan & Sarah Wordsworth & Ruth Clifford & Pauline Robbe & Jenny C. Taylor & Anna Schuh & Samantha J. L. Knight
July 2017, Volume 35, Issue 7
- 669-672 Defining Value: The Need for a Longer, Broader View
by Tomas J. Philipson & Sachin Kamal-Bahl & Anupam B. Jena - 673-683 Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview
by Erik J. Dasbach & Elamin H. Elbasha - 685-695 Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis
by Daisuke Goto & Ya-Chen Tina Shih & Pascal Lecomte & Melvin Olson & Chukwukadibia Udeze & Yujin Park & C. Daniel Mullins - 697-716 Discrete Choice Experiments: A Guide to Model Specification, Estimation and Software
by Emily Lancsar & Denzil G. Fiebig & Arne Risa Hole - 717-726 Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Lesley Uttley & Sophie Whyte & Timothy Gomersall & Shijie Ren & Ruth Wong & Duncan Chambers & Paul Tappenden - 727-740 Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature
by Maarten J. IJzerman & Hendrik Koffijberg & Elisabeth Fenwick & Murray Krahn - 741-753 An Investigation of the Overlap Between the ICECAP-A and Five Preference-Based Health-Related Quality of Life Instruments
by Lidia Engel & Duncan Mortimer & Stirling Bryan & Scott A. Lear & David G. T. Whitehurst
June 2017, Volume 35, Issue 6
- 607-612 How Qualitative Methods Can be Used to Inform Model Development
by Samantha Husbands & Susan Jowett & Pelham Barton & Joanna Coast - 613-624 Bayesian Methods for Calibrating Health Policy Models: A Tutorial
by Nicolas A. Menzies & Djøra I. Soeteman & Ankur Pandya & Jane J. Kim - 637-646 Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities?
by Paul Mark Mitchell & Sridhar Venkatapuram & Jeff Richardson & Angelo Iezzi & Joanna Coast - 647-659 An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis
by Paul Tappenden & Susannah Sadler & Martin Wildman - 661-663 Comment on: “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal”
by Odette Reifsnider & Fiona Hall & Sonja Sorensen & Irina Proskorovsky & Isabelle Girod & Jennifer Lee - 665-667 Response to Letter to the Editor Regarding “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal”
by Bram L. T. Ramaekers & Rob Riemsma & Florian Tomini & Thea Asselt & Sohan Deshpande & Steven Duffy & Nigel Armstrong & Johan L. Severens & Jos Kleijnen & Manuela A. Joore
May 2017, Volume 35, Issue 5
- 493-500 Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System?
by Alan Lyles - 501-515 Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Systematic Literature Review
by Melina Dritsaki & Felix Achana & James Mason & Stavros Petrou - 517-535 Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review
by James Brockbank & Sorrel Wolowacz - 537-547 Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Christopher Carroll & Paul Tappenden & Rachid Rafia & Jean Hamilton & Duncan Chambers & Mark Clowes & Paul Durrington & Nadeem Qureshi & Anthony S. Wierzbicki - 549-559 Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland–Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data
by Jason Madan & Kamran A. Khan & Stavros Petrou & Sarah E. Lamb - 561-573 Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study
by Matthew Franklin & Sarah Davis & Michelle Horspool & Wei Sun Kua & Steven Julious - 575-589 The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling
by Asrul Akmal Shafie & Hui Yee Yeo & Laurent Coudeville & Lucas Steinberg & Balvinder Singh Gill & Rohani Jahis & Amar-Singh HSS - 591-601 Making Implicit Assumptions Explicit in the Costing of Informal Care: The Case of Head and Neck Cancer in Ireland
by Paul Hanly & Rebecca Maguire & Myles Balfe & Eleanor O’Sullivan & Linda Sharp - 603-604 Comment on: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”
by Afschin Gandjour - 605-606 Authors’ Reply to Gandjour: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”
by Monika Wagner & Mireille Goetghebeur
April 2017, Volume 35, Issue 4
- 397-413 Economic Studies in Motor Neurone Disease: A Systematic Methodological Review
by Alan Moore & Carolyn A. Young & Dyfrig A. Hughes - 415-424 Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Benjamin Kearns & Abdullah Pandor & Matt Stevenson & Jean Hamilton & Duncan Chambers & Mark Clowes & John Graham & M. Satish Kumar - 425-438 Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma
by Kelly Fust & Xiaoyan Li & Michael Maschio & Guillermo Villa & Anju Parthan & Richard Barron & Milton C. Weinstein & Luc Somers & Caroline Hoefkens & Gary H. Lyman - 439-451 Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration?
by Brendan Mulhern & Richard Norman & Paula Lorgelly & Emily Lancsar & Julie Ratcliffe & John Brazier & Rosalie Viney - 453-467 Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15
by Christine Mpundu-Kaambwa & Gang Chen & Remo Russo & Katherine Stevens & Karin Dam Petersen & Julie Ratcliffe - 469-478 Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and US
by Renske J. Hoefman & Job Exel & Werner B. F. Brouwer - 479-491 A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
by C. Rinciog & M. Watkins & S. Chang & T. M. Maher & C. LeReun & D. Esser & A. Diamantopoulos
March 2017, Volume 35, Issue 3
- 259-269 Weighing Clinical Evidence Using Patient Preferences: An Application of Probabilistic Multi-Criteria Decision Analysis
by Henk Broekhuizen & Maarten J. IJzerman & A. Brett Hauber & Catharina G. M. Groothuis-Oudshoorn - 271-296 A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder
by Ifigeneia Mavranezouli & Joran Lokkerbol - 297-318 A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies
by Ching-Yun Wei & Ruben G. W. Quek & Guillermo Villa & Shravanthi R. Gandra & Carol A. Forbes & Steve Ryder & Nigel Armstrong & Sohan Deshpande & Steven Duffy & Jos Kleijnen & Peter Lindgren - 319-329 How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review
by Xinyang Hua & Thomas Wai-Chun Lung & Andrew Palmer & Lei Si & William H. Herman & Philip Clarke - 331-345 The Valuation of Informal Care in Cost-of-Illness Studies: A Systematic Review
by Juan Oliva-Moreno & Marta Trapero-Bertran & Luz Maria Peña-Longobardo & Raúl del Pozo-Rubio - 347-362 Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence
by Richard Abreu Lourenco & Marion Haas & Jane Hall & Rosalie Viney - 363-373 Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
by Irina A. Tikhonova & Martin W. Hoyle & Tristan M. Snowsill & Chris Cooper & Joanna L. Varley-Campbell & Claudius E. Rudin & Ruben E. Mujica Mota - 375-396 Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)
by Michael Willis & Pierre Johansen & Andreas Nilsson & Christian Asseburg
February 2017, Volume 35, Issue 2
- 129-139 Emergent Challenges in Determining Costs for Economic Evaluations
by Josephine C. Jacobs & Paul G. Barnett - 141-162 Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus
by Asrul Akmal Shafie & Chin Hui Ng & Yui Ping Tan & Nathorn Chaiyakunapruk - 163-176 Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy
by Anthony J. Hatswell & Nick Freemantle & Gianluca Baio - 177-190 Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update
by Spencer M. Vale & Dane Hill & Steven R. Feldman - 191-202 Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
by Bram L. T. Ramaekers & Rob Riemsma & Florian Tomini & Thea Asselt & Sohan Deshpande & Steven Duffy & Nigel Armstrong & Johan L. Severens & Jos Kleijnen & Manuela A. Joore - 203-213 A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence
by Ros Wade & Robert Hodgson & Mousumi Biswas & Melissa Harden & Nerys Woolacott - 215-223 A Review of US Drug Costs Relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010–2016
by Jacquelyn McRae & F. Randy Vogenberg & Silky Webb Beaty & Elizabeth Mearns & Stefan Varga & Laura Pizzi - 225-235 Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK
by Richard Lawson & James Ryan & Frederic King & Jo Wern Goh & Eszter Tichy & Kevin Marsh - 237-248 Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom
by Lindsay Claxton & Robert Hodgson & Matthew Taylor & Bill Malcolm & Ruth Pulikottil Jacob - 249-258 Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
by Erik Landfeldt & Lars Alfredsson & Volker Straub & Hanns Lochmüller & Katharine Bushby & Peter Lindgren
December 2017, Volume 35, Issue 1
- 1-3 Heath State Utility Values for Cost-Effectiveness Models
by Jonathan Karnon - 5-6 Special Edition on Utility Measurement, PharmacoEconomics
by Andrew Lloyd - 7-9 Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care
by Roberta Ara & Tessa Peasgood & Clara Mukuria & Helene Chevrou-Severac & Donna Rowen & Ismail Azzabi-Zouraq & Suzy Paisley & Tracey Young & Ben Hout & John Brazier - 11-19 International Regulations and Recommendations for Utility Data for Health Technology Assessment
by Donna Rowen & Ismail Azzabi Zouraq & Helene Chevrou-Severac & Ben Hout - 21-31 A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models
by John Brazier & Roberta Ara & Donna Rowen & Helene Chevrou-Severac - 33-41 The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment
by Donna Rowen & John Brazier & Roberta Ara & Ismail Azzabi Zouraq - 43-55 The Identification, Review and Synthesis of Health State Utility Values from the Literature
by Roberta Ara & John Brazier & Tessa Peasgood & Suzy Paisley - 57-66 The Use of Mapping to Estimate Health State Utility Values
by Roberta Ara & Donna Rowen & Clara Mukuria - 67-75 Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies
by Roberta Ara & John Brazier & Tracey Young - 77-88 The Use of Health State Utility Values in Decision Models
by Roberta Ara & John Brazier & Ismail Azzabi Zouraq - 89-94 Estimating Health State Utility Values for Comorbidities
by Roberta Ara & John Brazier
January 2017, Volume 35, Issue 1
- 1-4 Measuring the Value of Pharmaceuticals in the US Health System
by Surrey M. Walton & Anirban Basu & John Mullahy & Samuel Hong & Glen T. Schumock - 5-13 Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine
by Mike Paulden & James F. O’Mahony & Christopher McCabe - 15-24 Modeling Treatment Sequences in Pharmacoeconomic Models
by Ying Zheng & Feng Pan & Sonja Sorensen - 25-42 The Societal Cost of Schizophrenia: A Systematic Review
by Huajie Jin & Iris Mosweu - 43-63 Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations
by Simon van der Schans & Lucas M. A. Goossens & Melinde R. S. Boland & Janwillem W. H. Kocks & Maarten J. Postma & Job F. M. van Boven & Maureen P. M. H. Rutten-van Mölken - 65-82 Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations
by Obinna I. Ekwunife & James F. O’Mahony & Andreas Gerber Grote & Christoph Mosch & Tatjana Paeck & Stefan K. Lhachimi - 83-95 Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review
by Mahdi Gharaibeh & J. Lyle Bootman & Ali McBride & Jennifer Martin & Ivo Abraham - 97-109 Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Paul Tappenden & Sue Harnan & Shijie Ren & Praveen Thokala & Ruth Wong & Clara Mukuria & Clare Green & Simon Pledge & John Tidy - 111-124 Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)
by Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson - 125-128 Benefits, Challenges and Potential Strategies of Open Source Health Economic Models
by William C. N. Dunlop & Nicola Mason & James Kenworthy & Ron L. Akehurst
December 2016, Volume 34, Issue 12
- 1195-1209 Using Best–Worst Scaling to Investigate Preferences in Health Care
by Kei Long Cheung & Ben F. M. Wijnen & Ilene L. Hollin & Ellen M. Janssen & John F. Bridges & Silvia M. A. A. Evers & Mickael Hiligsmann - 1211-1225 Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review
by Surasak Saokaew & Ajaree Rayanakorn & David Bin-Chia Wu & Nathorn Chaiyakunapruk - 1227-1239 The Value of Medicines: A Crucial but Vague Concept
by Fernando Antoñanzas & Robert Terkola & Maarten Postma - 1241-1253 Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rachid Rafia & Alison Scope & Sue Harnan & John W. Stevens & Matt Stevenson & Alan Lobo - 1255-1265 Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study
by Pei-Jung Lin & Cayla J. Saret & Peter J. Neumann & Eileen A. Sandberg & Joshua T. Cohen - 1267-1276 The Pharmacoeconomic Evaluation Process in Ireland
by Laura McCullagh & Michael Barry - 1277-1297 Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases
by Paul S. J. Miller & Harry Hill & Fredrik L. Andersson - 1299-1308 Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
by Christiaan Dolk & Martin Eichner & Robert Welte & Anastassia Anastassopoulou & Laure-Anne Van Bellinghen & Barbara Poulsen Nautrup & Ilse Van Vlaenderen & Ruprecht Schmidt-Ott & Markus Schwehm & Maarten Postma
November 2016, Volume 34, Issue 11
- 1071-1074 From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare
by Matthijs Versteegh & Saskia Knies & Werner Brouwer - 1075-1086 Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation
by Padraig Dixon & George Davey Smith & Stephanie von Hinke & Neil M. Davies & William Hollingworth - 1087-1100 Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies
by Feng Xie & Bruno Kovic & Xuejing Jin & Xiaoning He & Mengxiao Wang & Camila Silvestre - 1101-1110 The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence
by Eleftherios Sideris & Mark Corbett & Stephen Palmer & Nerys Woolacott & Laura Bojke - 1111-1131 A Methodological Review of US Budget-Impact Models for New Drugs
by Josephine Mauskopf & Stephanie Earnshaw - 1133-1144 Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis
by Matthijs Versteegh - 1145-1159 Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK
by Jamie Elvidge & Ash Bullement & Anthony J. Hatswell - 1161-1172 Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations
by Cynthia P. Iglesias & Alexander Thompson & Wolf H. Rogowski & Katherine Payne - 1173-1186 Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience
by François Bocquet & Anaïs Loubière & Isabelle Fusier & Anne-Laure Cordonnier & Pascal Paubel - 1187-1188 Discretely Integrated Condition Event Simulation for Pharmacoeconomics
by Mondher Toumi & Ekkehard Beck & Steve Sherman & Leyla Mohseninejad & Samuel Aballéa - 1189-1190 Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics
by J. Jaime Caro
October 2016, Volume 34, Issue 10
- 967-969 Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?
by Livio Garattini & Alessandro Curto - 971-980 Sustainable Financing of Innovative Therapies: A Review of Approaches
by Aidan Hollis - 981-992 Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence
by Alexis Llewellyn & Rita Faria & Beth Woods & Mark Simmonds & James Lomas & Nerys Woolacott & Susan Griffin - 993-1004 EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes
by Mark Oppe & Kim Rand-Hendriksen & Koonal Shah & Juan M. Ramos‐Goñi & Nan Luo - 1005-1014 The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan
by Haruhisa Fukuda & Shunya Ikeda & Takeru Shiroiwa & Takashi Fukuda - 1015-1022 Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3
by Ron D. Hays & Dennis A. Revicki & David Feeny & Peter Fayers & Karen L. Spritzer & David Cella - 1023-1038 A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy
by Paul Tappenden & Shijie Ren & Rachel Archer & Rebecca Harvey & Marrissa Martyn-St James & Hasan Basarir & John Stevens & Alan Lobo & Sami Hoque - 1039-1050 Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer
by Bonny Parkinson & Rosalie Viney & Marion Haas & Stephen Goodall & Preeyaporn Srasuebkul & Sallie-Anne Pearson - 1051-1065 BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles
by William C. N. Dunlop & C. Daniel Mullins & Olaf Pirk & Ron Goeree & Maarten J. Postma & Ashley Enstone & Louise Heron - 1067-1070 Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?
by T. Joseph Mattingly & C. Daniel Mullins & Eberechukwu Onukwugha
September 2016, Volume 34, Issue 9
- 829-831 Model Validation: Has it’s Time Come?
by Jonathan Karnon - 833-845 Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer
by Pieter T. Boer & Geert W. J. Frederix & Talitha L. Feenstra & Pepijn Vemer - 847-861 Cost Effectiveness of HPV Vaccination: A Systematic Review of Modelling Approaches
by Joshua Pink & Ben Parker & Stavros Petrou - 901-912 The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence
by James Lomas & Alexis Llewellyn & Marta Soares & Mark Simmonds & Kath Wright & Alison Eastwood & Stephen Palmer - 913-923 Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial
by Stéphane Verguet & Jane J. Kim & Dean T. Jamison - 925-937 Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland
by Susanne Schmitz & Laura McCullagh & Roisin Adams & Michael Barry & Cathal Walsh - 939-951 The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
by Lisa Nagy & Terho Heikkinen & Alfred Sackeyfio & Richard Pitman - 953-966 Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
by Melanie J. Davies & Divina Glah & Barrie Chubb & Gerasimos Konidaris & Phil McEwan
August 2016, Volume 34, Issue 8
- 723-731 Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges
by Sevan Dirmesropian & James G. Wood & C. Raina MacIntyre & Philippe Beutels & Anthony T. Newall - 741-750 Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective
by P. Thokala & E. L. Simpson & P. Tappenden & J. W. Stevens & K. Dickinson & S. Ryder & P. Harrison - 805-814 The Impact of Different DCE-Based Approaches When Anchoring Utility Scores
by Richard Norman & Brendan Mulhern & Rosalie Viney - 815-827 Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
by Jonathan Graham & Doreen McBride & Donald Stull & Anna Halliday & Stamatia Theodora Alexopoulos & Maria-Magdalena Balp & Matthew Griffiths & Ion Agirrezabal & Torsten Zuberbier & Alan Brennan
July 2016, Volume 34, Issue 7
- 625-627 Why Cancer?
by Alan Haycox - 635-644 Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine
by Gregory S. Zaric - 645-649 Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?
by Milad Karimi & John Brazier - 651-664 Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches
by James Shearer & Paul McCrone & Renee Romeo - 673-680 Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Hazel Squires & Matt Stevenson & Emma Simpson & Rebecca Harvey & John Stevens - 681-707 Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease
by Luis Hernandez & Asli Ozen & Rodrigo DosSantos & Denis Getsios - 709-721 Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
by Krithika Rajagopalan & David Trueman & Lydia Crowe & Daniel Squirrell & Antony Loebel
June 2016, Volume 34, Issue 6
- 529-531 Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective
by Kenneth Boyd & Peter Hall - 533-550 Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension
by Shuyan Gu & Huimei Hu & Hengjin Dong - 551-567 Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals
by Jagpreet Chhatwal & Tianhua He & Maria A. Lopez-Olivo - 569-585 A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus
by Martin Henriksson & Ramandeep Jindal & Catarina Sternhufvud & Klas Bergenheim & Elisabeth Sörstadius & Michael Willis - 587-596 Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence
by Sebastian Hinde & Ros Wade & Stephen Palmer & Nerys Woolacott & Eldon Spackman - 597-608 Identification of Evidence for Key Parameters in Decision-Analytic Models of Cost Effectiveness: A Description of Sources and a Recommended Minimum Search Requirement
by Suzy Paisley - 609-616 Biosimilars: How Can Payers Get Long-Term Savings?
by Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud - 617-624 Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health
by Salah Ghabri & Françoise F. Hamers & Jean Michel Josselin
May 2016, Volume 34, Issue 5
- 423-426 Pharmaceutical Price Schemes in Europe: Time for a ‘Continental’ One?
by Livio Garattini & Alessandro Curto & Nick Freemantle - 427-433 Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?
by Beth Woods & Rita Faria & Susan Griffin - 435-446 Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment
by Aris Angelis & Panos Kanavos - 447-461 Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches
by Dyfrig Hughes & Joanna Charles & Dalia Dawoud & Rhiannon Tudor Edwards & Emily Holmes & Carys Jones & Paul Parham & Catrin Plumpton & Colin Ridyard & Huw Lloyd-Williams & Eifiona Wood & Seow Tien Yeo - 463-477 Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Abdullah Pandor & Daniel Pollard & Tim Chico & Robert Henderson & Matt Stevenson - 479-498 Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature
by Simon Frey & Carl R. Blankart & Tom Stargardt - 499-508 Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life Care
by Joanna Coast & Elisabeth Huynh & Philip Kinghorn & Terry Flynn - 509-520 Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study
by Kathryn Coyle & Doug Coyle & Julie Blouin & Karen Lee & Mohammed F. Jabr & Khai Tran & Lisa Mielniczuk & John Swiston & Mike Innes - 521-527 EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria
by Emma Hawe & Doreen McBride & Maria-Magdalena Balp & Haijun Tian & Anna Halliday & Donald E. Stull
April 2016, Volume 34, Issue 4
- 323-329 Should the Lambda (λ) Remain Silent?
by Hossein Haji Ali Afzali & Jonathan Karnon & Mark Sculpher - 331-332 Richard Edlin, Christopher McCabe, Claire Hulme, Peter Hall, Judy Wright: Cost Effectiveness Modelling for Health Technology Assessment: A Practical Course
by Doug Coyle - 333-336 Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility
by Alexander Thompson & Bruce Guthrie & Katherine Payne - 337-348 The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence
by Joanne O’Connor & Stephen Rice & Alison Smith & Mark Rodgers & Rocio Rodriguez Lopez & Dawn Craig & Nerys Woolacott - 349-361 AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
by P. Vemer & I. Corro Ramos & G. A. K. Voorn & M. J. Al & T. L. Feenstra - 363-391 Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
by Sylvain Druais & Agathe Doutriaux & Magali Cognet & Annabelle Godet & Christophe Lançon & Pierre Levy & Ludovic Samalin & Pascal Guillon - 393-402 What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study
by Anthony Harris & Jing Jing Li & Karen Yong - 403-417 Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa
by Ilanca Fraser & Johanita Burger & Martie Lubbe & George Dranitsaris & Mark Sonderup & Tienie Stander - 419-420 Comment on: “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review”
by Angelo Claudio Palozzo & Andrea Messori - 421-422 Authors’ Reply to Palozzo and Messori: ‘‘Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review’’
by Bonny Parkinson & Adam G. Elshaug
March 2016, Volume 34, Issue 3
- 217-220 PCSK9 Inhibitors: A Technology Worth Paying For?
by William S. Weintraub & Samuel S. Gidding - 217-220 PCSK9 Inhibitors: A Technology Worth Paying For?
by William Weintraub & Samuel Gidding - 221-224 Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?
by Livio Garattini & Anna Padula & Milene Costa - 221-224 Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?
by Livio Garattini & Anna Padula & Milene Rangel Costa - 225-226 Zaheer-Ud-Din Babar (ed): Pharmaceutical Prices in the 21st Century
by Suzanne Rose Hill - 225-226 Zaheer-Ud-Din Babar (ed): Pharmaceutical Prices in the 21st Century
by Suzanne Hill - 227-244 Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community
by Bernhard Ultsch & Oliver Damm & Philippe Beutels & Joke Bilcke & Bernd Brüggenjürgen & Andreas Gerber-Grote & Wolfgang Greiner & Germaine Hanquet & Raymond Hutubessy & Mark Jit & Mirjam Knol & Rüdiger Kries & Alexander Kuhlmann & Daniel Levy-Bruhl & Matthias Perleth & Maarten Postma & Heini Salo & Uwe Siebert & Jürgen Wasem & Ole Wichmann - 227-244 Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community
by Bernhard Ultsch & Oliver Damm & Philippe Beutels & Joke Bilcke & Bernd Brüggenjürgen & Andreas Gerber-Grote & Wolfgang Greiner & Germaine Hanquet & Raymond Hutubessy & Mark Jit & Mirjam Knol & Rüdiger Kries & Alexander Kuhlmann & Daniel Levy-Bruhl & Matthias Perleth & Maarten Postma & Heini Salo & Uwe Siebert & Jürgen Wasem & Ole Wichmann - 245-257 Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Munira Essat & Paul Tappenden & Shijie Ren & Alice Bessey & Rachel Archer & Ruth Wong & Alan Lobo & Sami Hoque - 245-257 Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Munira Essat & Paul Tappenden & Shijie Ren & Alice Bessey & Rachel Archer & Ruth Wong & Alan Lobo & Sami Hoque - 259-272 Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges
by Jordana K. Schmier & Carolyn K. Hulme-Lowe - 259-272 Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges
by Jordana Schmier & Carolyn Hulme-Lowe - 273-284 Are Efficient Designs Used in Discrete Choice Experiments Too Difficult for Some Respondents? A Case Study Eliciting Preferences for End-of-Life Care
by Terry N. Flynn & Marcel Bilger & Chetna Malhotra & Eric A. Finkelstein - 273-284 Are Efficient Designs Used in Discrete Choice Experiments Too Difficult for Some Respondents? A Case Study Eliciting Preferences for End-of-Life Care
by Terry Flynn & Marcel Bilger & Chetna Malhotra & Eric Finkelstein - 285-301 Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation
by Monika Wagner & Hanane Khoury & Jacob Willet & Donna Rindress & Mireille Goetghebeur - 285-301 Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation
by Monika Wagner & Hanane Khoury & Jacob Willet & Donna Rindress & Mireille Goetghebeur - 303-314 Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania
by Amani Mori & Ole Norheim & Bjarne Robberstad - 303-314 Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania
by Amani Thomas Mori & Ole Frithjof Norheim & Bjarne Robberstad - 315-322 Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives
by Jill Bindels & Bram Ramaekers & Isaac Ramos & Leyla Mohseninejad & Saskia Knies & Janneke Grutters & Maarten Postma & Maiwenn Al & Talitha Feenstra & Manuela Joore - 315-322 Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives
by Jill Bindels & Bram Ramaekers & Isaac Corro Ramos & Leyla Mohseninejad & Saskia Knies & Janneke Grutters & Maarten Postma & Maiwenn Al & Talitha Feenstra & Manuela Joore
February 2016, Volume 34, Issue 2
- 91-93 Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis
by Eberechukwu Onukwugha - 91-93 Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis
by Eberechukwu Onukwugha - 95-100 Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects Models
by William H. Crown - 95-100 Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects Models
by William Crown - 101-106 Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats
by Brendan Collins - 107-114 NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big Data
by Owen Johnson & Peter Hall & Claire Hulme - 107-114 NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big Data
by Owen A. Johnson & Peter S. Hall & Claire Hulme - 115-126 Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research
by Deborah Marshall & Lina Burgos-Liz & Kalyan Pasupathy & William Padula & Maarten IJzerman & Peter Wong & Mitchell Higashi & Jordan Engbers & Samuel Wiebe & William Crown & Nathaniel Osgood - 115-126 Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research
by Deborah A. Marshall & Lina Burgos-Liz & Kalyan S. Pasupathy & William V. Padula & Maarten J. IJzerman & Peter K. Wong & Mitchell K. Higashi & Jordan Engbers & Samuel Wiebe & William Crown & Nathaniel D. Osgood - 127-138 National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment
by Nalin Payakachat & J. Mick Tilford & Wendy J. Ungar - 127-138 National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment
by Nalin Payakachat & J. Tilford & Wendy Ungar - 139-154 Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015
by Paula K. Lorgelly & Brett Doble & Rachel J. Knott - 139-154 Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015
by Paula Lorgelly & Brett Doble & Rachel Knott - 155-160 Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities
by Miqdad Asaria & Katja Grasic & Simon Walker - 155-160 Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities
by Miqdad Asaria & Katja Grasic & Simon Walker - 161-168 Validation of the Hospital Episode Statistics Outpatient Dataset in England
by Joanna C. Thorn & Emma Turner & Luke Hounsome & Eleanor Walsh & Jenny L. Donovan & Julia Verne & David E. Neal & Freddie C. Hamdy & Richard M. Martin & Sian M. Noble - 161-168 Validation of the Hospital Episode Statistics Outpatient Dataset in England
by Joanna Thorn & Emma Turner & Luke Hounsome & Eleanor Walsh & Jenny Donovan & Julia Verne & David Neal & Freddie Hamdy & Richard Martin & Sian Noble - 169-179 Understanding Adherence and Prescription Patterns Using Large-Scale Claims Data
by Margrét V. Bjarnadóttir & Sana Malik & Eberechukwu Onukwugha & Tanisha Gooden & Catherine Plaisant - 169-179 Understanding Adherence and Prescription Patterns Using Large-Scale Claims Data
by Margrét Bjarnadóttir & Sana Malik & Eberechukwu Onukwugha & Tanisha Gooden & Catherine Plaisant - 181-194 Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment
by Caroline Canavan & Joe West & Timothy Card - 181-194 Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment
by Caroline Canavan & Joe West & Timothy Card - 195-205 Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease
by Chris Schilling & Duncan Mortimer & Kim Dalziel & Emma Heeley & John Chalmers & Philip Clarke - 195-205 Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease
by Chris Schilling & Duncan Mortimer & Kim Dalziel & Emma Heeley & John Chalmers & Philip Clarke - 207-216 Cost Prediction Using a Survival Grouping Algorithm: An Application to Incident Prostate Cancer Cases
by Eberechukwu Onukwugha & Ran Qi & Jinani Jayasekera & Shujia Zhou - 207-216 Cost Prediction Using a Survival Grouping Algorithm: An Application to Incident Prostate Cancer Cases
by Eberechukwu Onukwugha & Ran Qi & Jinani Jayasekera & Shujia Zhou
January 2016, Volume 34, Issue 1
- 1-3 Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016
by Yot Teerawattananon & Alia Luz - 1-3 Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016
by Yot Teerawattananon & Alia Luz - 5-11 The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?
by James F. O’Mahony & Diarmuid Coughlan - 5-11 The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?
by James O’Mahony & Diarmuid Coughlan - 13-22 Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers
by Elamin H. Elbasha & Jagpreet Chhatwal - 13-22 Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers
by Elamin Elbasha & Jagpreet Chhatwal